

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A composition for treating sexual dysfunction by pulmonary inhalation, said composition comprising apomorphine, the apomorphine being in the form of a free base, pharmaceutically acceptable salt or ester,

wherein the composition provides a nominal dose of apomorphine of from ~~about 100 200~~ to ~~about 1600 1200~~ micrograms of apomorphine or a pharmaceutically acceptable salt or ester thereof (based on the weight of the hydrochloride salt);

wherein the administration of the composition by pulmonary inhalation provides a C_{max} within 1 to 5 minutes of administration;

wherein the composition is a dry powder composition; and

wherein the apomorphine has a mass median aerodynamic diameter of 10 μ m or less.

2. (Original) A composition as claimed in claim 1, wherein the apomorphine is apomorphine hydrochloride.

3. (Cancelled).

4. (Previously presented) A composition as claimed in claim 1, wherein the C_{max} is at least 2ng/ml.

5. (Original) A composition as claimed in claim 4, wherein the C_{max} is at least 7ng/ml.

6. (Previously Presented) A composition as claimed in claim 1, wherein the administration of the composition by pulmonary inhalation provides a terminal elimination half-life of between 50 and 70 minutes.

7. (Previously Presented) A composition as claimed in claim 1, wherein the administration of the composition by pulmonary inhalation provides a dose dependent $AUC_{0-\infty}$.
8. (Previously Presented) A composition as claimed in claim 1, wherein the administration of the composition by pulmonary inhalation provides a dose dependent AUC_{0-t} .
9. (Previously Presented) A composition as claimed in claim 1, wherein the administration of the composition by pulmonary inhalation provides a dose dependent C_{max} .
10. (Previously Presented) A composition as claimed in claim 1, wherein the administration of the composition by pulmonary inhalation is not accompanied with the adverse side effects usually associated with the administration of apomorphine.
11. (Cancelled).
12. (Cancelled)
13. (Currently amended) A composition as claimed in claim 1 ~~12~~, wherein the dose is from about 300 to about 1200 micrograms.
14. (Original) A composition as claimed in claim 13, wherein the dose is from about 400 to about 1000 micrograms.
15. (Previously Presented) A composition as claimed in claim 1, wherein the sexual dysfunction is erectile dysfunction.
16. (Previously Presented) A composition as claimed in claim 1, wherein the sexual dysfunction is female sexual dysfunction.

17. (Original) A composition as claimed in claim 15, wherein the erectile dysfunction is psychogenic.

18. (Original) A composition as claimed in claim 15, wherein the erectile dysfunction is organic.

19 to 20. (Cancelled).

21. (Previously presented) A composition as claimed in claim 1, wherein the mass median aerodynamic diameter is 5 μ m or less.

22. (Previously presented) A composition as claimed in claim 1, wherein at least 90% of the apomorphine has a particle size of 10 μ m or less.

23. (Original) A composition as claimed in claim 22, wherein at least 90% of the apomorphine has a particle size of 5 μ m or less.

24. (Previously presented) A composition as claimed in claim 1, wherein the composition further comprises an additive material.

25. (Original) A composition as claimed in claim 24, wherein the additive material is provided in an amount from about 0.15% to about 5% of the composition, by weight.

26. (Previously Presented) A composition as claimed in claim 24, wherein the additive material is selected from the group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate.

27. (Previously presented) A composition as claimed in claim 1, wherein the composition further comprises an excipient material.

28. (Original) A composition as claimed in claim 27, wherein the excipient material is in the form of carrier particles having an average particle size of 40 to 70 μ m.

29. (Previously Presented) A composition as claimed in claim 1, wherein the composition comprises a solution pMDI formulation including a propellant, a solvent and water.

30. (Original) A composition as claimed in claim 29, wherein the propellant is HFA134a and/or HFA227.

31. (Previously Presented) A composition as claimed in claim 29, wherein the solvent is ethanol.

32. (Previously Presented) A composition as claimed in claim 29, wherein said water is present in an amount from greater than 2% by weight to about 10% by weight of the solution pMDI formulation.

33. (Previously Presented) A composition as claimed in claim 1, wherein the composition is a suspension pMDI formulation including a propellant.

34. (Original) A composition as claimed in claim 33, wherein the propellant is HFA134a and/or HFA227.

35. (Original) A composition as claimed in claim 34, wherein the propellant includes about 60% by weight HFA134a and about 40% by weight HFA227.

36 to 41. (Cancelled)

42. (Previously Presented) A dry powder inhaler device comprising a composition as claimed in claim 1.

43. (Original) A dry powder inhaler device as claimed in claim 42, wherein the inhaler is an active inhaler.

44. (Previously Presented) A dry powder inhaler as claimed in claim 42, wherein the inhaler is a breath actuated inhaler device.

45. (Previously Presented) A blister for use in a dry powder inhaler device as claimed in claim 42, wherein the blister contains the composition.

46. (Original) A blister as claimed in claim 45, wherein the blister is a foil blister.

47. (Previously Presented) A blister as claimed in claim 45, wherein the blister comprises polyvinyl chloride or polypropylene in contact with the composition.